title: Clinical implications of the JAK2 V617F mutation in essential thrombocythemia.
authors.forename: E
authors.initials: E
authors.lastname: Antonioli
authors.forename: P
authors.initials: P
authors.lastname: Guglielmelli
authors.forename: A
authors.initials: A
authors.lastname: Pancrazzi
authors.forename: C
authors.initials: C
authors.lastname: Bogani
authors.forename: M
authors.initials: M
authors.lastname: Verrucci
authors.forename: V
authors.initials: V
authors.lastname: Ponziani
authors.forename: G
authors.initials: G
authors.lastname: Longo
authors.forename: A
authors.initials: A
authors.lastname: Bosi
authors.forename: A M
authors.initials: AM
authors.lastname: Vannucchi
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D005260:Female; D006801:Humans; D053614:Janus Kinase 2; D008297:Male; D008875:Middle Aged; D009154:Mutation / Q000235:genetics*; D016133:Polymerase Chain Reaction; D011505:Protein-Tyrosine Kinases / Q000235:genetics*; D011518:Proto-Oncogene Proteins / Q000235:genetics*; D013920:Thrombocythemia, Essential / Q000175:diagnosis / Q000201:enzymology / Q000235:genetics*
chemical_list: D011518:Proto-Oncogene Proteins; D011505:Protein-Tyrosine Kinases; C507924:JAK2 protein, human; D053614:Janus Kinase 2